Aminobenzoic acids and derivatives
Medchemexpress LLC Pergolide (mesylate) | 66104-23-2 | 410.59 | 50 MG
Pergolide mesylate, an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. It can be used for Parkinson's disease and hyperprolactinaemia research.
- Potent and orally active dopamine D1 and D2 receptors agonist.
- Inhibits H2O2-induced cell death in SH-SY5Y neuroblastoma cells.
- Protects SH-SY5Y neuroblastoma cells from cell death at low concentrations.
- Reduces working/reference memory errors in a rat model of Parkinson's disease.
- Facilitates spatial memory and improves brain oxidative balance in animal models.
Medchemexpress LLC Pridinol mesylate | 6856-31-1 | MFCD00079241 | 100.0% | 391.52 g/mol | C21H29NO4S | 10 MG
Pridinol mesylate is an anticholinergic muscle relaxant provided as the methanesulfonate salt for research and analytical applications. It is supplied as a high-purity analytical standard with defined storage recommendations for stability.
Apexbio Technology LLC Obatoclax mesylate (GX15-070) 803712-79-0 25mg
Obatoclax mesylate (GX15-070) is a small-molecule inhibitor targeting multiple anti-apoptotic proteins within the BCL-2 family including BCL-2 BCL-XL MCL-1 A1 and BCL-B It functions by binding to their BH3-binding grooves thereby disrupting interactions with pro-apoptotic proteins such as Bak and Bim promoting apoptotic processes Obatoclax mesylate induces apoptosis in cultured acute myeloid leukemia (AML) cells and primary AML patient samples evidencing inhibitory effects on clonogenic growth with IC50 values below 200 nmol/L In preclinical research applications this compound shows activity in xenograft models of solid tumors and multiple myeloma providing a relevant chemical tool for oncology research focused on apoptotic mechanisms and hematologic malignancies
Apexbio Technology LLC Dabrafenib Mesylate (GSK-2118436) 1195768-06-9 10mM (in 1mL DMSO)
Dabrafenib Mesylate (GSK-2118436 CAS 1195768-06-9) is a potent orally active inhibitor that specifically targets the mutant BRAF kinase variant V600E BRAF functions as a serine/threonine kinase essential in the MAPK/ERK signaling cascade frequently mutated in various human cancers Dabrafenib selectively inhibits BRAF V600E (IC50 0 8 nM) with lower activity against wild-type B-Raf and c-Raf By binding and disrupting BRAF V600E activity dabrafenib attenuates downstream MAPK/ERK activation leading to reduced cellular proliferation and tumorigenicity This agent is useful for investigating oncogenic pathways and was FDA-approved for metastatic melanoma with BRAF V600E mutation
Medchemexpress LLC Lenvatinib (mesylate) | 857890-39-2 | 99.7% | 522.96 | 1 G
Lenvatinib mesylate is an oral, multi-targeted tyrosine kinase inhibitor that potently inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities. It is intended for research use only.
- Potent inhibition of multiple tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET.
- Demonstrates potent antitumor activities.
- Inhibits local tumor growth and metastasis in vivo.
- Decreases microvessel density in xenograft models.
Medchemexpress LLC Lazertinib mesylate | 2247995-37-3 | 99.9% | 650.75 | 25 MG
Lazertinib mesylate is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. It inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib mesylate can be used in the study of non-small cell lung cancer.
- Potent, selective, CNS-penetrant, orally available, and irreversible EGFR tyrosine kinase inhibitor.
- High selectivity for activating (EGFRm) and T790M resistance mutations.
- Inhibits phosphorylation of EGFR, AKT, and ERK.
- Leads to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models.
- Applicable in the study of non-small cell lung cancer.
- IC50 & Target: EGFRT790M.
Medchemexpress LLC Lazertinib (mesylate) | 2247995-37-3 | 99.9% | 650.75 | 10 MG
Lazertinib mesylate is a potent, selective, CNS-penetrant, orally available, and irreversible EGFR tyrosine kinase inhibitor. It exhibits high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib mesylate inhibits phosphorylation of EGFR, AKT, and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. It can be used in the study of non-small cell lung cancer.
- Potent, selective, CNS-penetrant, orally available, and irreversible EGFR tyrosine kinase inhibitor.
- High selectivity for activating (EGFRm) and T790M resistance mutations.
- Inhibits phosphorylation of EGFR, AKT, and ERK.
- Leads to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models.
- Can be used in the study of non-small cell lung cancer.
Apexbio Technology LLC Nafamostat 81525-10-2 50mg
Nafamostat (CAS 81525-10-2) is a small-molecule inhibitor targeting a broad spectrum of serine proteases including thrombin plasmin kallikrein and human trypsin It is designed to block protease-mediated hydrolysis reactions thereby regulating coagulation pathways and inflammation-related protease activity Nafamostat exerts its biological activity primarily through reversible binding to protease active sites inhibiting their enzymatic functions In biochemical assays Nafamostat demonstrates potent inhibitory activity with an IC50 value of approximately 1 10 nM against human trypsin Based on these pharmacological properties Nafamostat holds research potential in coagulation pathway studies inflammation-related protease research pancreatitis modeling and mechanistic investigations of blood coagulation disorders and inflammatory responses
Medchemexpress LLC Almitrine mesylate | 29608-49-9 | MFCD01679060 | 99.8% | 669.8 g/mol | C28H37F2N7O6S2 | 1 ML
Almitrine mesylate is a research chemical that functions as a peripheral chemoreceptor agonist and selectively inhibits Ca2+-dependent K+ channels. It is supplied as a ready-to-use 10 mM solution in DMSO (1 mL) for laboratory research use only.
- Acts as a peripheral chemoreceptor agonist.
- Selectively inhibits Ca2+-dependent K+ channels.
- Provided as a 10 mM solution in DMSO for experimental convenience.
- High purity suitable for research assays.
- Characterized by formula C28H37F2N7O6S2 and molecular weight 669.8 g/mol.
Apexbio Technology LLC LENVATINIB-MESYLATE-25MG
lenvatinib Mesylate (CAS No 857890-39-2) is an oral tyrosine kinase inhibitor researched extensively in oncology Originating as a synthetic compound its mechanism of action involves targeting multiple receptor tyrosine kinases (RTKs) associated with tumor growth angiogenesis and progression These include VEGFR FGFR and PDGFR pathways In vitro lenvatinib Mesylate demonstrates activity in the nanomolar to low micromolar range indicating its potency It is widely applied in various cancer cell models and animal studies for testing therapeutic efficacy and understanding tumor biology Lenatatinib Mesylate is also used in drug screening programs to identify its effects and potential combinations with other therapies Experimental concentrations typically depend on the specific research design
Aobchem 2-Bromo-5-chloro-4-methylbenzoic acid | ≥97% | CAS 1426923-27-4 | C8H6BrClO2 | 1g
2-Bromo-5-chloro-4-methylbenzoic acid | ≥97% | CAS 1426923-27-4 | C8H6BrClO2 | 1g